A rare side effect of bone-strengthening drugs such as zoledronic acid and denosumab, given for cancer in the bones, in which a patch of jawbone is exposed in the mouth and does not heal. A dental check before starting and avoiding tooth extractions during treatment lower the risk.
The MASCC/ISOO/ASCO guideline (2019) defines medication-related osteonecrosis of the jaw by three criteria: current or previous treatment with a bone-modifying agent or angiogenic inhibitor; exposed bone, or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region, persisting for longer than 8 weeks; and no history of radiotherapy to the jaws or metastatic disease to the jaws. For people starting a bone-modifying agent, preventive care includes a comprehensive dental assessment, discussion of modifiable risk factors and avoiding elective dentoalveolar surgery during treatment; whether to pause the drug before dental surgery remains uncertain. Staging should be done by an experienced clinician, conservative measures come first, and the guideline stresses collaboration between dentist, dental specialist and oncologist. The radiotherapy exclusion is what separates it from osteoradionecrosis.
Showing the molecule this term concerns: Zoledronic acid.
Shares Bone-modifying agents (bisphosphonates, denosumab), Denosumab, Zoledronic acid and the tag supportive-care-gaps-2026-11.
Shares Bone-modifying agents (bisphosphonates, denosumab), Denosumab, Zoledronic acid.
Shares Pamidronate, Denosumab, Zoledronic acid.
Shares Pamidronate, Zoledronic acid.
Shares Bone-modifying agents (bisphosphonates, denosumab), Denosumab.
Shares Pamidronate, Zoledronic acid.
Shares Bone-modifying agents (bisphosphonates, denosumab), Denosumab.
Shares Bone-modifying agents (bisphosphonates, denosumab), Denosumab, Zoledronic acid.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/